David Pyrce Assumes Role of Chief Executive Officer at Cognigenics, Inc., Driving Leadership in RNA-Based Gene Therapies

Stuart, FL, January 16, 2024 (Business Wire) -- Cognigenics, Inc., a pioneering force in RNA-based gene therapies focused on memory loss, cognitive decline, anxiety related to mild cognitive impairment, and various neurodegenerative and neuropsychiatric diseases, appoints David Pyrce as the company's newly appointed Chief Executive Officer. Pryce brings Wall Street and capital market experience as well as over 30 years in pharma and biotech.

Read full article here.